Clinical trials: Immunodeficiency
Activated PI3Kdelta Syndrome (APDS); PASLI Disease
Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI
This study is designed to provide long-term CDZ173 treatment, a selective PI3Kδ inhibitor, to the patients with genetically activated PI3Kδ, i.e., patients with APDS/PASLI who participated in the CCDZ173X2201 study or who were…
- Trial name
- NCT02859727
- Testing
- CDZ173
- Where
- 8 sites in United States, Belarus and 5 more
- Volunteers
- 37 people
- Sponsor
- Pharming Technologies B.V.
HIV Infections
HealthMindr App to Increase Pre-exposure Prophylaxis (PrEP) Uptake and Retention Among Men Who Have Sex With Men (MSM)
This study is a randomized controlled clinical trial of a theoretically based mobile app, HealthMindr, to increase pre-exposure prophylaxis (PrEP) uptake among men who have sex with men (MSM) to prevent human immunodeficiency…
- Trial name
- NCT03763942
- Testing
- HealthMindr App, Control App
- Where
- 3 sites in United States
- Volunteers
- 658 people, healthy volunteers welcome
- Sponsor
- Emory University
Kaposi's Sarcoma
PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma
RATIONALE: PTC299 may stop the growth of Kaposi sarcoma by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of PTC299 and to see how well it works in treating patients…
- Trial name
- NCT00686842
- Testing
- VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- AIDS Malignancy Consortium
Primary Immune Deficiency Disorders (PIDD)
Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)
The purpose of this study is to determine if NABI-IGIV (10%) [Immune Globulin Intravenous (Human), 10%] is safe and effective in preventing serious bacterial infections (SBIs) in the treatment of patients with primary immune…
- Trial name
- NCT00538915
- Testing
- Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]
- Where
- 17 sites in United States
- Volunteers
- 63 people
- Sponsor
- ADMA Biologics, Inc.
HIV/AIDS, Sexually Transmitted Diseases
Innovative Tools to Expand HIV Self-Testing
The I-TEST study builds upon two participatory approaches, open challenge contests and entrepreneurship training. The study utilizes open challenge contest to generate youth-driven interventions on strategies to promote HIV…
- Trial name
- I-TEST (NCT04070287)
- Testing
- SMART Pack, Luv Box, Bili Vibes
- Where
- Nigeria
- Volunteers
- 388 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Chronic Lymphocytic Leukemia, Fatigue
Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase II trial studies how well lenalidomide and ofatumumab work in treating participants with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Conditions
- Chronic Lymphocytic Leukemia, Fatigue, Fever, Hypogammaglobulinemia
- Trial name
- NCT01002755
- Testing
- Lenalidomide, Ofatumumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
HIV Infections
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects
Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes).
- Trial name
- MOTIVATE 1 (NCT00098306)
- Testing
- Maraviroc (UK-427,857), Optimized Background Therapy
- Where
- 22 sites in United States, Canada
- Volunteers
- 601 people
- Sponsor
- ViiV Healthcare
HIV Infections
Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults
The purpose of this study is to evaluate the safety and pharmacokinetics of PC-1005 gel when used as a rectal microbicide in HIV-uninfected men and women (cis or transgender) with a history of consensual receptive anal…
- Trial name
- NCT03408899
- Testing
- PC-1005 gel
- Where
- 2 sites in United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
"The Once A Day Protease Inhibitor Regimens"
Atazanavir (ATV) and fosamprenavir (fAPV) are new protease inhibitors that can be administered once-a-day and boosted with ritonavir (r).
- Trial name
- NCT00242216
- Testing
- ritonavir-boosted atazanavir, ritonavir-boosted fosamprenavir
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- The University of Texas Health Science Center, Houston
HIV
Antiretroviral Therapy for Advanced HIV Disease in South Africa
This study will determine how well four different antiretroviral drug therapies work in patients with advanced HIV disease. The trial is part of the South Africa-U.S.
- Trial name
- NCT00342355
- Testing
- Zidovudine, Stavudine, Didanosine
- Where
- 7 sites in South Africa
- Volunteers
- 1,771 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Healthy Volunteers
Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers
Background: Rivaroxaban and apixaban are blood thinners. People with HIV may need to take them to treat or prevent blood clots. The anti-HIV drug darunavir (DRV) can increase the amount of these blood thinners in the body.
- Trial name
- NCT03864406
- Testing
- Cobicistat, Darunavir/Cobicistat, Rivaroxaban
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hiv
HOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients
The primary objective of this study is to determine if an HIV-infected deceased kidney donor (HIVD+) transplant is safe with regards to major transplant-related and HIV-related complications.
- Trial name
- NCT03500315
- Testing
- HIV D+/R+
- Where
- 29 sites in United States
- Volunteers
- 207 people
- Sponsor
- Johns Hopkins University
Chronic Granulomatous Disease
Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease
This study is for patients with chronic granulomatous disease (CGD), which is a disorder of the immune system that puts them at risk for severe infections.
- Trial name
- MUNCHR (NCT00578643)
- Testing
- Busulfan, Alemtuzumab, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Baylor College of Medicine
Adherence, Patient, Pre-Exposure Prophylaxis
mHealth Technologies to Enhance PrEP Adherence Among Thai MSM
This study aims to: 1) adapt the theory-based P3 (Prepared, Protected, emPowered) app designed to improve pre-exposure prophylaxis (PrEP) adherence, retention in PrEP clinical care, and PrEP persistence among young gay, bisexual…
- Conditions
- Adherence, Patient, Pre-Exposure Prophylaxis, HIV/AIDS
- Trial name
- P3-T (NCT04413708)
- Testing
- P3-T PrEP Adherence App
- Where
- Thailand
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Duke University
HIV-associated Enteropathy
Impact of SBI, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy
The purpose of the study is to evaluate the effectiveness of the oral nutritional therapy serum-derived bovine immunoglobulin protein isolate (SBI) 2.5 g twice a day (BID) and SBI 5.0 g versus placebo on supporting nutrient…
- Trial name
- NCT01828593
- Testing
- Serum-derived bovine immunoglobulin protein isolate (SBI)
- Where
- 10 sites in United States
- Volunteers
- 103 people
- Sponsor
- Entera Health, Inc
HIV Infections
Raltegravir Intensification in HIV-infected Patients
The purpose of this study is to determine whether treatment with Raltegravir further decreases HIV viral replication in HAART-suppressed, HIV-infected patients, potentially improving immune response to antiretroviral therapy.
- Trial name
- NCT00631449
- Testing
- Raltegravir
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Hereditary Angioedema
Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks
The study objective was to evaluate the safety and efficacy of repeat use of C1INH-nf for the treatment of acute HAE attacks.
- Trial name
- CHANGE 2 (NCT00438815)
- Testing
- C1 esterase inhibitor [human] (C1INH-nf)
- Where
- 30 sites in United States
- Volunteers
- 113 people
- Sponsor
- Shire
HIV Infections
Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response
A research study to measure the effect on CD4 counts of adding to current anti-retroviral regimen raltegravir with or without hyper-immune bovine colostrum.
- Trial name
- CORAL (NCT00772590)
- Testing
- Raltegravir, Hyper-immune Bovine Colostrum, raltegravir and hyper-immune bovine colostrum
- Volunteers
- 75 people
- Sponsor
- Kirby Institute
HIV, HIV Infections
Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
The objective of this study is to evaluate the safety and efficacy of a regimen containing cobicistat-boosted atazanavir (ATV+COBI) plus emtricitabine/tenofovir disoproxil fumarate (Truvada®; FTC/TDF) fixed-dose combination (FDC)…
- Trial name
- NCT01108510
- Testing
- COBI, RTV, ATV
- Where
- 134 sites in United States, Australia and 17 more
- Volunteers
- 698 people
- Sponsor
- Gilead Sciences
Human Immunodeficiency Virus
Evaluation of Kaletra Therapy Over the Long-term
Long term observation of patients under lopinavir/ritonavir containing therapy
- Trial name
- NCT01083810
- Testing
- Lopinavir/Ritonavir (Kaletra)
- Where
- 90 sites in Germany
- Volunteers
- 284 people
- Sponsor
- Abbott
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.